신체질환을 앓고 있는 정신과환자에서의 정신약물의 사용 II -새로운 정신약물을 중심으로

키워드

참고문헌 (180)

1. 이경규, "신체질환을 앓고 있는 정신과환자에서의 정신약물의 사용", 생물치료정신의학, 13(2), pp.158~169 (2007), 대한생물치료정신의학회
2. Ackerman S, "Bodyweight Gain Induced by Psychotropic Drugs: Incidence, Mechanisms and Management", CNS Drugs, 9, pp.135~151 (1998)
3. Keck PE, "Bipolar Disorder, Obesity, and Pharmacotherapy-Associated Weight Gain", J Clin Psychiatry, 64, pp.1426~1435 (2003)
4. McElroy SL, "Are Mood Disorders and Obesity Related? A Review for the Mental Health Professional", J Clin Psychiatry, 65, pp.634~651 (2004)
5. Schwartz TL, "Psychiatric medication-induced obesity: a review", Obes Rev, 5, pp.115~121 (2004)
6. Vanina Y, "Body Weight Changes Associated With Psychopharmacology", Psychiatr Serv, 53, pp.842~847 (2002)
7. Allison DB, "The Distribution of Body Mass Index Among Individuals With and Without Schizophrenia", J Clin Psychiatry, 60, pp.215~220 (1999)
8. Baptista T, "Body weight gain induced by antipsychotic drugs: mechanisms and management", Acta Psychiatr Scand, 100, pp.3~16 (1999)
9. Sechter D, "the Amisulpride Study Group. Amisulpride vs. Risperidone in Chronic Schizophrenia: Results of a 6- month. Double-blind Study", Neuropsychopharmacology, 27, pp.1071~1081 (2002)
10. Mahe V, "Lack of weight gain during amisulpride treatment", Eur Neuropsychopharmacol, 11(Suppl 4), pp.S292~ (2001)
11. Kolotkin RL, "Changes in weight and weight-related quality of life in a multicentre, randomized trial of aripiprazole versus standard of care" (2008), Eur Psychiatry In press, Corrected Proof
12. Kerwin R, "A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study", Eur Psychiatry, 22, pp.433~443 (2007)
13. Lamberti S, "Weight gain among schizophrenic patients treated with clozapine", Am J Psychiatry, 149, pp.689~690 (1992)
14. Meyer JM, "Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: Prospective data from phase 1", Schizophr Res, 101, pp.273~286 (2008)
15. Gupta S, "Olanzapine: weight gain and therapeutic efficacy", J Clin Psychopharmacology, 19, pp.273~274 (1999)
16. Tran P, "Double blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders", J Clin Psychopharmacology, 17, pp.407~418 (1997)
17. Perez-Iglesias R, "Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: Findings of a randomized clinical trial in a drug-naive population", Schizophr Res, 99, pp.13~22 (2008)
18. Marder SR, "Efficacy and Safety of Paliperidone Extended-Release Tablets: Results of a 6-Week, Randomized, Placebo-Controlled Study", Biol Psychiatry, 62, pp.1363~1370 (2007)
19. Arvanitis LA, "Multiple fixed doses of “Seroquel”(Quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo", Biol Psychiatry, 42, pp.233~236 (1997)
20. Adler CM, "Safety and tolerability of quetiapine in the treatment of acute mania in bipolar disorder", J Affect Disord, 100(Suppl 1), pp.S15~S22 (2007)
21. Gunasekara NS, "A review of its use in schizophrenia", CNS Drugs, 9, pp.325~340 (1998)
22. Ganguli R, "Weight gain over 4 months in schizophrenia patients: a comparison of olanzapine and risperidone", Schizophr Res, 49, pp.261~267 (2001)
23. Peuskens J, "Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multicentered, double-blind, parallel-group study versus haloperidol", Br J Psychiatry, 166, pp.712~733 (1995)
24. Wirshing D, "Novel antipsychotics: weight gain liabilities", J Clin Psychiatry, 60, pp.358~363 (1999)
25. Taylor DM, "Atypical antipsychotics and weight gain- a systematic review", Acta Psychiatr Scand, 101, pp.416~432 (2000)
26. Ratner Y, "Effectiveness, safety, and tolerability of ziprasidone for treating schizophrenia patients undergoing usual care: A 12- month, open-label, flexible-dose, naturalistic observational trial", Prog Neuropsychopharmacol Biol Psychiatry, 31, pp.1401~1409 (2007)
27. Lin WW, "Clinical efficacy, body weight change and cardiac safety of zotepine in schizophrenic patients", Eur Neuropsychopharmacol, 16(Suppl 4), pp.S415~S416 (2006)
28. Allison DB, "Antipsychotic-induced weight gain: a comprehensive research synthesis", Am J Psychiatry, 156, pp.1686~1696 (1999)
29. Adams CE, "Chlorpromazine versus placebo for schizophrenia", Cochrane Database Syst Rev, 18 (2007)
30. Bernstein J, "Psychotropic drug induced weight gain: mechanism and management", Clin Neuropharmacol, 11, pp.194~206 (1988)
31. Fava M, "Weight gain and antidepressants", J Clin Psychiatry, 61(Suppl 11), pp.S37~S41 (2000)
32. Aronne LJ, "Weight gain in the treatment of mood disorders", J Clin Psychiatry, 64(Suppl 8), pp.S22~S29 (2003)
33. Kraus T, "Body weight, the tumor necrosis factor system and leptin production during treatment with mirtazapine or venlafaxine", Pharmacopsychiatry, 35, pp.220~225 (2002)
34. Silverstone PH, "Once-daily venlafaxine extended release(XR) compared with fluoxetine in outpatients with depression and anxiety", J Clin Psychiatry, 60, pp.22~28 (1999)
35. Raskin J, "Duloxetine in the long-term treatment of major depressive disorder", J Clin Psychiatry, 64, pp.1237~1244 (2003)
36. Perahia DGS, "Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial", Eur Psychiatry, 21, pp.367~378 (2006)
37. Zimmermann U, "Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients", J Psychiatr Res, 37, pp.193~220 (2003)
38. Montgomery SA, "A 24-Week Randomized, Double-Blind, Placebo- Controlled Study of Escitalopram for the Prevention of Generalized Social Anxiety Disorder", J Clin Psychiatry, 66, pp.1270~1278 (2005)
39. Michelson D, "Changes in weight during a 1-year trial of fluoxetine", Am J Psychiatry, 156, pp.1170~1176 (1999)
40. Abell CA, "Placebo controlled double-blind trial of fluvoxamine maleate in the obese", J Psychosom Res, 30, pp.143~146 (1986)
41. Hinze-Selch D, "Effects of antidepressants on weight and on the plasma levels of leptin, TNF and soluble TNF receptors: a longitudinal study in patients treated with amitriptyline or paroxetine", Neuropsychopharmacology, 23, pp.13~19 (2000)
42. Fava M, "Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment", J Clin Psychiatry, 61, pp.863~867 (2000)
43. Fernstrom MH, "Resting metabolic rate is reduced in patients treated with antidepressants", Biol Psychiatry, 20, pp.692~695 (1985)
44. Fernstrom MH, "Drugs that cause weight gain", Obesity Research, 3(Suppl 4), pp.S435~S439 (1995)
45. Croft H, "Effect on body weight of bupropion sustained-release in patients with major depression treated for 52 weeks", Clin Ther, 24, pp.662~672 (2002)
46. Gadde KM, "Bupropion for weight loss: An investigation of efficacy and tolerability in overweight and obese women", Obesity Research, 9, pp.544~551 (2001)
47. Fawcett J, "Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression", J Affect Disord, 51, pp.267~285 (1998)
48. Sussman N, "Weight effects of nefazodone, bupropion, mirtazapine, and venlafaxine: A review of the available evidence", Primary Psychiatry, 7, pp.33~48 (2000)
49. Zimmermann U, "Effect of naltrexone on weight gain and food craving induced by tricyclic antidepressants and lithium: an open study", Biol Psychiatry, 41, pp.747~749 (1997)
50. Fagiolini A, "Prevalence of Obesity and Weight Change During Treatment in Patients With Bipolar I Disorder", J Clin Psychiatry, 63, pp.528~533 (2002)
51. Schou M, "Pharmacological and clinical problems of lithium prophylaxis", Br J Psych, 116, pp.615~619 (1970)
52. Vendsborg PB, "Lithium treatment and weight gain", Acta Psych Scand, 53, pp.139~147 (1976)
53. Vestergaard P, "Prospective studies on a lithium cohort 3: tremor, weight gain, diarrhea, psychological complaints", Acta Psych Scand, 78, pp.434~441 (1988)
54. Atmaca M, "Weight gain and serum leptin levels in patients on lithium treat ment", Neuropsychobiology, 46, pp.67~69 (2002)
55. Mathew B, "Lithium-induced changes in the body mass index", Acta Psych Scand, 80, pp.538~540 (1989)
56. Baptista T, "Lithium and body weight gain", Pharmacopsychiatry, 28, pp.35~44 (1995)
57. Nasrallah A, "Carbamazepine and valproate for the treatment of bipolar disorder: a review of the literature", J Affect Disord, 95, pp.69~78 (2006)
58. Chengappa KNR, "Changes in body weight and body mass index among psychiatric patients receiving lithium, valproate, or topiramate: An open-label, nonrandomized chart review", Clin Ther, 24, pp.1576~1584 (2002)
59. Davis R, "Valproic acid: a reappraisal of its pharmacological properties and clinical efficacy in epilepsy", Drugs, 47, pp.332~342 (1994)
60. Sussman N, "Effect of psychotropic drugs on weight", Psychiatric Annals, 29, pp.580~594 (1999)
61. Verrotti A, "Serum leptin changes in epileptic patients who gain weight after therapy with Valproic acid", Neurology, 53, pp.230~232 (1999)
62. DeToledo JC, "Changes in body weight with chronic, high dose gabapentin therapy", Ther Drug Monit, 19, pp.394~396 (1997)
63. Hogan RE, "Total percentage body weight changes during addon therapy with tiagabine, carbamazepine and phenytoin", Epilepsy Res, 41, pp.23~28 (2000)
64. David Chadwick and for the Vigabatrin European Monotherapy Study Group, "Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre randomised double-blind study", Lancet, 354, pp.13~19 (1999)
65. Calabrese JR, "A double-blind, placebocontrolled, prophylaxis study of lamotrigine in rapidcycling bipolar disorder", J Clin Psychiatry, 61, pp.841~850 (2000)
66. Rosenfeld W, "Weight loss patterns with topiramate therapy", Epilepsia, 38, pp.60~63 (1997)
67. Gordon A, "Mood stabilization and weight loss with topiramate", Am J Psychiatry, 156, pp.968~969 (1999)
68. Evans S, "Food “craving” and the acute effect of alprazolam on food intake in women with premenstrual dysphoric disorder", Appetite, 32, pp.331~349 (1999)
69. Physicians’ Desk Reference, "Montvale" (2000), NJ: Medical Economics Data Production Company
70. Vanina Y, "Body Weight Changes Associated With Psychopharmacology", Psychiatr Serv, 53, pp.842~847 (2002)
71. Dixon L, "Prevalence and correlates of diabetes in national schizophrenia samples", Schizophr Bull, 26, pp.903~912 (2000)
72. Bushe C, "Prevalence of diabetes and impaired glucose tolerance in patients with schizophrenia", Br J Psychiatry, 47(Supp l), pp.S67~71 (2004)
73. Haddad PM, "Antipsychotics and diabetes: review of non-prospective data", Br J Psychiatry, 47(Suppl), pp.S80~S86 (2004)
74. Kohen D, "Diabetes mellitus and schizophrenia: historical perspective", Br J Psychiatry, 47(Supp l), pp.S64~S66 (2004)
75. Ryan MC, "Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia", Am J Psychiatry, 160, pp.284~289 (2003)
76. Lindenmeyer JP, "Changes in glucose and cholesterol levels in patients with schizophrenia treat-ed with typical or atypical antipsychotics", Am J Psy-chiatry, 160, pp.290~296 (2003)
77. Lieberman JA, "Effectiveness of antipsychotic drugs in patients with chronic schizophrenia", N Engl J Med, 353, pp.1209~1223 (2005)
78. Singh R, "Mental health, antipsychotics and hyperglycaemia", Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 1, pp.209~224 (2007)
79. Haupt DW, "Differential metabolic effects of antipsychotic treatments", Eur Neuropsychopharmacol, 16(Suppl 3), pp.S149~S155 (2006)
80. De Hert MA, "Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication", Schizophr Res, 83, pp.87~93 (2006)
81. Pigott TA, "Aripiparzole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study", J Clin Psychiatry, 64, pp.1048~1056 (2003)
82. Lund BC, "Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claimsbased approach", Arch Gen Psychiatry, 58, pp.1172~1176 (2001)
83. Sernyak MJ, "Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia", Am J Psychiatry, 159, pp.561~566 (2002)
84. Gianfrancesco F, "Antipsychotic-induced type 2 diabetes: evidence from a large health plan database", J Clin Psychopharmacol, 23, pp.328~335 (2003)
85. Wirshing DA, "Risperidone-associated new-onset diabetes", Biol Psychiatry, 50, pp.148~149 (2001)
86. Citrome L, "Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients", Psychiatr Serv, 55, pp.1006~1013 (2004)
87. Kane J, "Treatment of schizophrenia with paliperidone extended-release tablets: A 6-week placebo- controlled trial", Schizophr Res, 90, pp.147~161 (2007)
88. Mallya A, "Resolution of hyperglycemia on risperidone discontinuation; a case report", J Clin Psychiatry, 63, pp.453~454 (2002)
89. Wilson DR, "New-onset diabetes and ketoacidosis with atypical antipsychotics", Schizophr Res, 59, pp.1~6 (2003)
90. Koller EA, "Risperidone-associated diabetes mellitus: a pharmacovigilance study", Pharmacotherapy, 23, pp.735~744 (2003)
91. Newcomer JW, "Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia", Arch Gen Psychiatry, 59, pp.337~345 (2002)
92. Simpson GM, "Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder", Am J Psychiatry, 161, pp.1837~1847 (2004)
93. Kudla D, "Effectiveness, tolerability, and safety of ziprasidone in patients with schizophrenia or schizoaffective disorder: Results of a multi-centre observational trial", Eur Psychiatry, 22, pp.195~202 (2007)
94. Newcomer JW, "Second-generation(atypical) antipsychotics and metabolic effects: a comprehensive literature review", CNS Drugs, 19(Suppl 1), pp.S1~S93 (2005)
95. Schwarz L, "Blood Sugar Levels in Patients Treated with Chlorpromazine", Am J Psychiatry, 125, pp.253~255 (1968)
96. Musselmana DL, "Relationship of depression to diabetes types 1 and 2: epidemiology, biology, and treatment", Biol Psychiatry, 54, pp.317~329 (2003)
97. Anderson RJ, "Lustman PJ. The prevalence of comorbid depression in adults with diabetes: a meta-analysis", Diabetes Care, 24, pp.1069~1078 (2001)
98. Eaton WW, "Depression and risk for onset of type II diabetes. A prospective population-based study", Diabetes Care, 19, pp.1097~1102 (1996)
99. Bisschop MI, "The longitudinal relation between chronic diseases and depression in older persons in the community: the Longitudinal Aging Study Amsterdam", J Clin Epidemiol, 57, pp.187~194 (2004)
100. Lustman PJ, "Depression and poor glycemic control: a meta-analytic review of the literature", Diabetes Care, 23, pp.934~942 (2000)
101. Lin EH, "Effects of enhanced depression treatment on diabetes self-care", Ann Fam Med, 4, pp.46~53 (2006)
102. Rubin RR, "Depression symptoms and antidepressant medicine use in Diabetes Prevention Program participants", Diabetes Care, 28, pp.830~837 (2005)
103. McIntyre RS, "The effect of antidepressants on glucose homeostasis and insulin sensitivity: synthesis and mechanism", Expert Opin Drug Saf, 5, pp.157~168 (2006)
104. Kajdasz DK, "Duloxetine for the Management of Diabetic Peripheral Neuropathic Pain: Evidence- Based Findings from Post Hoc Analysis of Three Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Studies", Clin Ther, 29, pp.2536~2546 (2007)
105. Maheux P, "Fluoxetine improves insulin sensitivity in obese patients with non-insulin-dependent diabetes mellitus independently of weight loss", Int J Obes Relat Metab Disord, 21, pp.97~102 (1997)
106. Gray DS, "A randomized double-blind clinical trial of fluoxetine in obese diabetics", Int J Obes Relat Metab Disord, 16(Suppl 4), pp.S67~S72 (1992)
107. Sindrup SH, "The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy", Clin Pharmacol Ther, 52, pp.547~552 (1992)
108. Oswald P, "Fluvoxamine-induced hyperglycaemia in a diabetic patient with comorbid depression", Int J Neuropsychopharmacol, 6, pp.85~87 (2003)
109. Gu¨ lseren L, "Comparison of fluoxetine and paroxetine in type II diabetes mellitus patients", Arch Med Res, 36, pp.159~165 (2005)
110. Lustman PJ, "Sertraline for prevention of depression recurrence in diabetes mellius: a randomized, double-blind, placebo-controlled trial", Arch Gen Psychiatry, 63, pp.521~529 (2006)
111. Brown LC, "Type of antidepressant therapy and risk of type 2 diabetes in people with depression", Diabetes Res Clini Prac, 79, pp.61~67 (2008)
112. Lustman PJ, "Factors influencing glycemic control in type 2 diabetes during acute- and maintenance-phase treatment of major depressive disorder with bupropion", Diabetes Care, 30, pp.459~466 (2007)
113. Himmerich H, "Changes in weight and glucose tolerance during treatment with mirtazapine", Diabetes Care, 29, pp.170~ (2006)
114. Amrein R, "Schmid-Burgk W. Interactions of moclobemide with concomitantly administered medication: evidence from pharmacological and clinical studies", Psychopharmacology( Berl), 106(Suppl), pp.S24~S31 (1992)
115. Dosterta P, "Review of the pharmacokinetics and metabolism of reboxetine, a selective noradrenaline reuptake inhibitor", Eur Neuropsychopharmacol, 7(Suppl 1), pp.S23~S35 (1997)
116. Taylor D, "The Maudsley Prescribing Guidelines, 9th ed" (2007), London and New York: Informa Healthcare
117. Ketter TA, "Mood stabilizers and atypical antipsychotics: bimodal treatments for bipolar disorder", Psychopharmacol Bull, 39, pp.120~146 (2006)
118. Stefan H, "Novel anticonvulsant drugs", Pharmacol Ther, 113, pp.165~183 (2007)
119. Doucet J, "Protein binding of digitoxin, valproate and phenytoin in sera from diabetics", Eur J Clin Pharmacol, 45, pp.577~579 (1993)
120. Schnabel T Jr, "Evaluation of the safety and side effects of antianxiety agents", Am J Medicine, 82(Suppl 1), pp.7~13 (1987)
121. Wagner J, "Non-benzodiazepines for the treatment of insomnia", Sleep Med Rev, 4, pp.551~581 (2000)
122. Kerr D, "Betaadrenoceptor blockade and hypoglycaemia. A randomised, double-blind, placebo controlled comparison of metoprolol CR, atenolol and propranolol LA in normal subjects", Br J Clin Pharmacol, 29, pp.685~693 (1990)
123. Bazire S, "Psychotropic drug directory 2005", pp.217~218 (2005), Salisbury: Fivepin
124. Harden CL, "Mood disorders in patients with epilepsy: epidemiology and management", CNS Drugs, 16, pp.291~302 (2002)
125. Lambert MV, "Depression in epilepsy: etiology, phenomenology, and treatment", Epilepsia, 409(Suppl 10), pp.S21~S47 (1999)
126. Blumer D, "Treatment of the interictal psychoses", J Clin Psychiatry, 61, pp.110~122 (2000)
127. Pisani F, "Effects of psychotropic drugs on seizure threshold", Drug Saf, 25, pp.91~110 (2002)
128. Stimmen GL, "Psychotropic druginduced reductions in seizure threshold: Incidence and consequences", CNS Drugs, 5, pp.37~50 (1996)
129. Jobe PC, "The serotonergic and noradrenergic effects of antidepressant drugs are anticonvulsant, not proconvulsant", Epilepsy Behav, 7, pp.602~619 (2005)
130. Marks RC, "Antipsychotic medications and seizures", Psychiatr Med, 9, pp.37~52 (1991)
131. Hedges D, "Antipsychotic medication and seizures: a review", Drugs Today(Barc), 39, pp.551~557 (2003)
132. Tracqui A, "Amisulpride poisoning: a report on two cases", Hum Exp Toxicol, 14, pp.294~298 (1995)
133. Tsai JF, "Aripiprazole-associated seizure", J Clin Psychiatry, 67, pp.995~996 (2006)
134. Malik AR, "Aripiprazole-induced seizure", Can J Psychiatry, 50, pp.186~ (2005)
135. Pacia SV, "Clozapine-related seizures: Exprerience with 5,629 patients", Neurology, 44, pp.2247~2249 (1994)
136. Dedges DW, "Antipsychotic medication and seizures: A review", Drugs Today(Barc), 39, pp.437~439 (2002)
137. Naber D, "Efficacy and adverse effects of clozapine in the treatment of schizophrenia and tardive dyskinesia-a retrospective study of 387 patients", Psychopharmacology (Berl), 99(Suppl), pp.S73~S76 (1989)
138. Treves IA, "EEG abnormalities in clozapine- treated schizophrenic patients", Eur Neuropsychopharmacol, 6, pp.93~94 (1996)
139. Popli AP, "Valproate and force control during clozapine treatment in schizophrenic patients", Schizophr Res, 24, pp.216~ (1997)
140. Amann BL, "EEG abnormalities associated with antipsychotics: a comparison of quetiapine, olanzapine, haloperidol and healthy subjects", Hum Psychopharmacol, 18, pp.641~646 (2003)
141. Pillmann F, "Electroencephalogram alterations during treatment with olanzapine", Psychopharmacology(Berl), 150, pp.216~219 (2000)
142. Lee KC, "Risk of seizures associated with psychotropic medications: Emphasis on new drugs and new findings", Expert Opin Drug Saf, 2, pp.233~247 (2003)
143. Woolley J, "Lowered seizure threshold on olanzapine", Br J Psychiatry, 178, pp.85~86 (2001)
144. Dogu O, "Seizures associated with quetiapine treatment", Ann Pharmacother, 37, pp.1224~1227 (2003)
145. Hedges DW, "New-onset seizure associated with quetiapine and olanzapine", Ann Pharmacother, 36, pp.437~439 (2002)
146. Janssen Pharmaceuticals, (2007), New Jersey: Janssen Pharmaceuticals
147. Janssen Pharmaceuticals, (2007), New Jersey: Janssen Pharmaceuticals
148. Alldredge BK, "Seizure risk associated with psychotropic drugs: clinical and pharmacokinetic considerations", Neurology, 53(Suppl 2), pp.S68~S75 (1999)
149. "New York: Pfizer Inc", 2007, ~
150. Hori M, "Convulsive seizures in schizophrenic patients induced by zotepine administration", Jpn J Psychiatry Neurol, 46, pp.161~167 (1992)
151. Markowitz JC, "Seizures with neuroleptics and antidepressants", Gen Hosp Psychiatry, 9, pp.135~141 (1987)
152. Borowicz KK, "Fluoxetine enhances the anticonvulsant effects of conventional antiepileptic drugs in maximal electroshock seizures in mice", Pharmacol Rep, 58, pp.83~90 (2006)
153. Pericic D, "Anticonvulsant effects of acute and repeated fluoxetine treatment in unstressed and stressed mice", Brain Res, 1033, pp.90~95 (2005)
154. Cuenca PJ, "Seizure secondary to citalopram overdose", J Emerg Med, 26, pp.177~181 (2004)
155. Kelly CA, "Comparative toxicity of citalopram and the newer antidepressants after overdose", J Toxicol Clin Toxicol, 42, pp.67~1 (2004)
156. Clinckers R, "In vivo modulatory action of extracellular glutamate on the anticonvulsant effects of hippocampal dopamine and serotonin", Epilepsia, 46, pp.828~836 (2005)
157. Pisani F, "Antidepressant drugs and seizure susceptibility: From in vitro data to clinical practice", Epilepsia, 40(Suppl 10), pp.S48~S56 (1999)
158. White CM, "Seizure resulting from a venlafaxine overdose", Ann Pharmacother, 32, pp.135~136 (1998)
159. Maramattom V, "Duloxetine-induced syndrome of inappropriate antidiuretic hormone secretion and seizures", Neurology, 66, pp.773~774 (2006)
160. Alper K, "Seizure Incidence in Psychopharmacological Clinical Trials: An Analysis of Food and Drug Administration(FDA) Summary Basis of Approval Reports", Biol Psychiatry, 62, pp.345~354 (2007)
161. Curran S, "Selecting an Antidepressant for Use in a Patient with Epilepsy: Safety Considerations", Drug Saf, 18, pp.125~133 (1998)
162. Mongomery SA, "Antidepressants and seizures: emphasis on newer agents and clinical implications", Int J Clin Pract, 59, pp.1435~1440 (2005)
163. Preskorn SH, "Tricyclic antidepressant-indu ced seizures and plasma drug concentration", J Clin Psychiatry, 54, pp.201~202 (1993)
164. Rosenstein DL, "Seizures associated with antidepressants: A review", J Clin Psychiatry, 54, pp.289~299 (1993)
165. Davidson J, "Seizures and bupropion: A review", J Clin Psychiatry, 50, pp.256~261 (1989)
166. Jefferson JW, "Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations", Clin Ther, 27, pp.1685~1695 (2005)
167. Tutka P, "Convulsant and anticonvulsant effects of bupropion in mice", Eur J Pharmacol, 499, pp.117~120 (2004)
168. Juckel G, "Epileptiform EEG Patterns Induced by Mirtazapine in Both Psychiatric Patients and Healthy Volunteers", J Clin Psychopharmacol, 23, pp.421~422 (2003)
169. Haq MZU, "Mirtazapine precipitated seizures: A case report", Prog Neuropsychopharmacol Biol Psychiatry, 32, pp.1076~1078 (2008)
170. Schiwy W, "Therapeutic and side-effect profile of a selective and reversible MAOA inhibitor, brofaromine. Results of dose-finding trials in depressed patients", J Neural Transm Suppl, 28, pp.33~44 (1989)
171. Ku¨ hn K, "Antidepressive treatment in patients with temporal lobe epilepsy and major depression: a prospective study with three different antidepressants", Epilepsy Behav, 4, pp.674~679 (2003)
172. "Electronic Medicines Compendium"[URL]
173. Miyamoto T, "Psychotic episodes during zonisamide treatment", Seizure, 9, pp.65~70 (2000)
174. Besag FM, "Behavioural effects of the newer antiepileptic drugs: an update", Expert Opin Drug Saf, 3, pp.1~8 (2004)
175. Sillanpa¨ a¨ M, "Prognosis of seizure recurrence after stopping antiepileptic drugs in seizure-free patients: A long-term population-based study of childhood- onset epilepsy", Epilepsy Behav, 8, pp.713~719 (2006)
176. Britton JW, "Antiepileptic drug withdrawal: literature review", Mayo Clin Proc, 77, pp.1378~1388 (2002)
177. Browne JL, "A review of alprazolam withdrawal", Drug Intell Clin Pharm, 20, pp.837~841 (1986)
178. Catalano G, "Seizures associated with buspirone overdose: case report and literature review", Clin Neuropharmacol, 21, pp.347~350 (1998)
179. Julou L, "Pharmacological and clinical studies of cyclopyrrolones: zopiclone and suriclone", Pharmacol Biochem Behav, 23, pp.653~659 (1985)
180. McConchie RD, "Disulfiram- induced de novo seizures in the absence of ethanol challenge", J Stud Alcohol, 44, pp.739~743 (1983)

관련 논문AI추천